articleNew England Journal of MedicineFeb 21, 2002BRONZE OA

Leptin-Replacement Therapy for Lipodystrophy

National Institutes of Health · National Institute of Diabetes and Digestive and Kidney Diseases · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

The adipocyte hormone leptin is important in regulating energy homeostasis. Since severe lipodystrophy is associated with leptin deficiency, insulin resistance, hypertriglyceridemia, and hepatic steatosis, we assessed whether leptin replacement would ameliorate this condition.

Methods

Nine female patients (age range, 15 to 42 years; eight with diabetes mellitus) who had lipodystrophy and serum leptin levels of less than 4 ng per milliliter (0.32 nmol per milliliter) received recombinant methionyl human leptin (recombinant leptin). Recombinant leptin was administered subcutaneously twice a day for four months at escalating doses to achieve low, intermediate, and high physiologic replacement levels of leptin.

No related works found for this paper.